Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer — GUIDE

Castration Resistant Prostatic Cancer Clinical Trial

Official title:
A Randomised Non-comparative Phase II Trial of Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Status Recruiting

Clinical Trial Summary

The purpose of this study is to see if a prostate cancer marker in the blood (mGSTP1) can be used to guide chemotherapy treatment. Based on the level of this blood marker, some men may be able to have breaks in treatment rather than having chemotherapy continuously which is the current standard of care. This study will tell us if having these treatment breaks guided by mGSTP1 can improve how men feel during treatment while still treating the prostate cancer effectively. Docetaxel is a chemotherapy drug that is approved to treat prostate cancer and has been used for many years to treat prostate cancer like yours. Your doctor has already discussed this with you and you have both agreed that docetaxel is the best treatment for you to have at this time. You will have already started this chemotherapeutic treatment with docetaxel.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Castration Resistant Prostatic Cancer
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant

Clinical Trial Details

NCT number	NCT04918810
Study type	Interventional
Source	Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Contact	Ronan Burder
Phone	03 8559 5088
Email	ronan.burder@petermac.org
Status	Recruiting
Phase	Phase 2
Start date	November 11, 2021
Completion date	June 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT05191017` - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC	Phase 1/Phase 2
Recruiting	`NCT05519449` - Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)	Phase 1
Recruiting	`NCT06242470` - A Study of MGC026 in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT04337580` - Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer	Phase 2
Recruiting	`NCT05252390` - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04833517` - Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)
Completed	`NCT03248570` - Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects	Phase 2